Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Cash from Operations came in at 7156000.0 in Q1 2026, up 46.95% YoY from 4869834.91 in Q1 2025, and up 38.83% on a QoQ basis from 11699000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Cash from Operations (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Cash from Operations data on file, last reported at 7156000.0 in Q1 2026.
- Quarterly Cash from Operations rose 46.95% year-over-year to 7156000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7838000.0 (up 85.87% YoY) and the FY2025 annual result came in at 19272000.0, up 75.53% from the prior year.
- Cash from Operations rose to 7156000.0 in Q1 2026, from 11699000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 17506000.0 in Q2 2025 to a low of 35641000.0 in Q4 2022.
- A 5-year average of 17150352.94 and a median of 15534000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 476.0% — and 2025, when it surged 218.48%.
- Tracing ENTA's Cash from Operations over 5 years: stood at 35641000.0 in 2022, then rose by 29.89% to 24988000.0 in 2023, then jumped by 32.76% to 16801000.0 in 2024, then soared by 30.37% to 11699000.0 in 2025, then surged by 38.83% to 7156000.0 in 2026.
- The last three Cash from Operations figures came in at 7156000.0 (Q1 2026), 11699000.0 (Q4 2025), and 6489000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -9.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.97 Mn |
| Jun 30, 2026 | -9.97 Mn |
| Mar 31, 2026 | -7.16 Mn |
| Mar 31, 2026 | -7.16 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Dec 31, 2025 | -11.70 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Sep 30, 2025 | -6.49 Mn |
| Jun 30, 2025 | 17.51 Mn |
| Jun 30, 2025 | 17.51 Mn |
| Mar 31, 2025 | -13.49 Mn |
| Mar 31, 2025 | -13.49 Mn |
| Dec 31, 2024 | -16.80 Mn |
| Dec 31, 2024 | -16.80 Mn |
| Sep 30, 2024 | -10.40 Mn |
| Sep 30, 2024 | -10.40 Mn |
| Jun 30, 2024 | -14.78 Mn |
| Jun 30, 2024 | -14.78 Mn |
| Mar 31, 2024 | -28.60 Mn |
| Mar 31, 2024 | -28.60 Mn |